Diabetes drug withdrawn after reports of hepatic eventsBMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7122.1559n (Published 13 December 1997) Cite this as: BMJ 1997;315:1559
- Jacqui Wise
The new diabetes drug troglitazone (Romozin) has been withdrawn from the market in Britain after an increasing number of reports of severe hepatic adverse events. The Food and Drug Administration in the United States, however, has decided that the benefits of treatment outweigh the risks, provided that patients receiving troglitazone are monitored frequently for …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial